Panagiotis (Takis) Prinos

Team Leader - Epigenetics Cellular Screening

University of Toronto

Panagiotis (Takis) completed his Ph.D. in Human Genetics and Developmental Biology from the University of Connecticut Health Center, Farmington, CT in 1998. After a post-doc on Molecular & Cellular Biology at IRCM in Montreal where he studied signaling pathways and control of gene expression during early embryonic development, he joined Aurelium BioPharma as senior scientist where he led the Cell Biology-Target Validation group from 2002-2006. During the next 5 years, he managed a Genome Canada project on the functional annotation of essential alternatively spliced isoforms in cancer at the Universite de Sherbrooke, Quebec. Subsequently, he directed the functional genomics/phenotypic platform at the Laboratory for Functional Genomics in Sherbrooke, Quebec. He joined the SGC in December, 2014 where he is leading the Oncology patient-derived tumor cell screening activities.

Takis' current interests include cell-based assays and phenotypic screening, assay development and validation, HCS/HTS screens and epigenetic pathways in tumorigenesis, cell survival and proliferation.  

Alternative splicing as a generator of functional diversity in cancer
Prinos, P, Klinck, R, Pereault, JP, Elela, SA, Chabot, B.
Med Sci. 2012 Vol. 1, 4, . doi:
PMID:

Proteins Associated with the Exon Junction Complex Also Control the Alternative Splicing of Apoptotic Regulators
Michelle L, Toutant J, Thibault P, Durand M, Garneau D, Lapointe E, Couture S, Le Hir H, Klinck R, Abou Elela S, Prinos P and Chabot B.
Mol Cell Biol. 2012 32(5):954-67. doi: 10.1128/MCB.06130-11
PMID: 22203037

RNAi-mediated knockdown of α-enolase increases the sensitivity of tumor cells to antitubulin chemotherapeutics
Georges E, Bonneau AM, Prinos P
Int J Biochem Mol Biol. 2011 2(4):303-8. doi:
PMID: 22187664

SYK alternative splicing regulates mitosis and cancer cell survival
Prinos P, Garneau D, Lucier JF, Gendron D, Couture S, Boivin M, Brosseau JP, Lapointe E, Thibault P, Durand M, Tremblay K, Gervais-Bird J, Nwilati H, Klinck R, Chabot B, Perreault JP, Wellinger RJ, Elela SA.
Nat Struct Mol Biol. 2011 18(6):673-9. doi: 10.1038/nsmb.2040
PMID: 21552259

Mutation of cysteine 21 inhibits nucleophosmin/B23 oligomerization and chaperone activity
Prinos P, Lacoste MC, Wong J, Bonneau AM, Georges, E.
Int J Biochem Mol Biol. 2011 2(1): 24-30. doi:
PMID: 21968505

2016

Chemical Biology Approaches for Characterization of Epigenetic Regulators.
Barsyte-Lovejoy D, Szewczyk MM, Prinos P, Lima-Fernandes E, Ackloo S, Arrowsmith CH
Meth. Enzymol.. 16.02.2016 574:79-103. doi: 10.1016/bs.mie.2016.01.011
PMID: 27423858

2015

Preclinical target validation using patient-derived cells.
Edwards AM, Arrowsmith CH, Bountra C, Bunnage ME, Feldmann M, Knight JC, Patel DD, Prinos P, Taylor MD, Sundström M, Barker P, Barsyte D, Bengtson MH, Bell C, Bowness P, Boycott KM, Buser-Doepner C, Carpenter CL, Carr AJ, Clark K, Das AM, Dhanak D, Dirks P, Ellis J, Fantin VR, Flores C, Fon EA, Frail DE, Gileadi O, O'Hagan RC, Howe T, Isaac JT, Jabado N, Jakobsson PJ, Klareskog L, Knapp S, Lee WH, Lima-Fernandes E, Lundberg IE, Marshall J, Massirer KB, MacKenzie AE, Maruyama T, Mueller-Fahrnow A, Muthuswamy S, Nanchahal J, O'Brien C, Oppermann U, Ostermann N, Petrecca K, Pollock BG, Poupon V, Prinjha RK, Rosenberg SH, Rouleau G, Skingle M, Slutsky AS, Smith GA, Verhelle D, Widmer H, Young LT
Nat Rev Drug Discov. 20.02.2015 14(3):149-50. doi: 10.1038/nrd4565
PMID: 25722227

2014

Tumor microenvironment-associated modifications of alternative splicing
Brosseau, J-P, Lucier, J-F, Nwilati, H, Thibault, P, Garneau, D, Durand, M, Couture, S, Lapointe, E, Prinos, P, Klinck, R, Perreault, J-P, Chabot, B, Abou-Elela, S.
RNA. 02.2014 20(2):189-201. doi: 10.1261/rna.042168
PMID: 24335142

2013

MBNL1 and RBFOX2 cooperate to establish a splicing programme involved in pluripotent stem cell differentiation
Venables, JP, Lapasset, L, Gadea, G, Fort, P, Klinck, R, Irimia, M, Vignal, E, Thibault, P, Prinos, P, Chabot, B, Abou Elela, S, Roux, P, Lemaitre, J-M, Tazi, J.
Nat Commun. 2013 4:2480. doi: 10.1038/ncomms3480
PMID: 24048253

Cancer-Associated Perturbations in Alternative Pre-messenger RNA Splicing
Shkreta L, Bell B, Revil T, Venables JP, Prinos P, Elela SA, Chabot B.
Cancer Treat Res. 2013 158:41-94. doi: 10.1007/978-3-642-31659-3_3
PMID: 24222354

RBFOX2 enforces the mesenchymal splicing signature in normal and cancer tissues
Venables, J, Brosseau, J-P, Gadea, G, Klinck, R, Prinos, P, Beaulieu, JF, Thibault, P, Tremblay, K, Rousset, F, Tazi, J, Abou Elela, S and Chabot, B.
Mol Cell Biol. 2013 33(2):396-405. doi:
PMID:

2012

Alternative splicing as a generator of functional diversity in cancer
Prinos, P, Klinck, R, Pereault, JP, Elela, SA, Chabot, B.
Med Sci. 11.15.2012 Vol. 1, 4, . doi:
PMID:

Proteins Associated with the Exon Junction Complex Also Control the Alternative Splicing of Apoptotic Regulators
Michelle L, Toutant J, Thibault P, Durand M, Garneau D, Lapointe E, Couture S, Le Hir H, Klinck R, Abou Elela S, Prinos P and Chabot B.
Mol Cell Biol. 03.15.2012 32(5):954-67. doi: 10.1128/MCB.06130-11
PMID: 22203037

2011

RNAi-mediated knockdown of α-enolase increases the sensitivity of tumor cells to antitubulin chemotherapeutics
Georges E, Bonneau AM, Prinos P
Int J Biochem Mol Biol. 2011 2(4):303-8. doi:
PMID: 22187664

Mutation of cysteine 21 inhibits nucleophosmin/B23 oligomerization and chaperone activity
Prinos P, Lacoste MC, Wong J, Bonneau AM, Georges, E.
Int J Biochem Mol Biol. 2011 2(1): 24-30. doi:
PMID: 21968505

SYK alternative splicing regulates mitosis and cancer cell survival
Prinos P, Garneau D, Lucier JF, Gendron D, Couture S, Boivin M, Brosseau JP, Lapointe E, Thibault P, Durand M, Tremblay K, Gervais-Bird J, Nwilati H, Klinck R, Chabot B, Perreault JP, Wellinger RJ, Elela SA.
Nat Struct Mol Biol. 06.18.2011 18(6):673-9. doi: 10.1038/nsmb.2040
PMID: 21552259

glqxz9283 sfy39587stf02 mnesdcuix8
sfy39587stf03